TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis: Updated

Current Pathobiology Reports

Volumn 3, Issue 4, 2015, Pages 291-305

  Dewidar, Bedair ^a,b   Soukupova, Jitka ^c   Fabregat, Isabel ^c,d   Dooley, Steven ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Tanta University   (Egypt)

^c BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Hepatic stellate cells; Liver fibrosis; Myofibroblasts; TGF

Indexed keywords

EID: 84976506290     PISSN: None     EISSN: 2167485X     Source Type: Journal    
DOI: 10.1007/s40139-015-0089-8     Document Type: Review

References (128)

1. Heldin CH, Miyazono K, ten Dijke P (1997) TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature 390:465–471. doi:10.1038/37284
2. Massagué J, Seoane J, Wotton D (2005) Smad transcription factors. Genes Dev. doi:10.1101/gad.1350705
3. • Dennler S, Itoh S, Vivien D, et al. (1998) Direct binding of Smad3 and Smad4 to critical TGF-β-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 17:3091–3100. doi:10.1093/emboj/17.11.3091. This study identified the Smad binding sites (CAGA) in the promoter of the TGF-β target gene PAI-1
4. Park SH (2005) Fine tuning and cross-talking of TGF-β signal by inhibitory Smads. J Biochem Mol Biol 38:9–16
5. Moustakas A, Heldin C-H (2005) Non-Smad TGF-β signals. J Cell Sci 118:3573–3584. doi:10.1242/jcs.02554
6. Zhang YE (2009) Non-Smad pathways in TGF-β signaling. Cell Res 19:128–139. doi:10.1038/cr.2008.328
7. Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA (2014) Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol 14:181–194. doi:10.1038/nri3623
8. Lee UE, Friedman SL (2011) Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 25:195–206. doi:10.1016/j.bpg.2011.02.005
9. Breitkopf K, Haas S, Wiercinska E et al (2005) Anti-TGF-β strategies for the treatment of chronic liver disease. Alcohol Clin Exp Res 29:121S–131S. doi:10.1097/01.alc.0000189284.98684.22
10. • Sancho P, Mainez J, Crosas-Molist E, et al. (2012) NADPH oxidase NOX4 mediates stellate cell activation and hepatocyte cell death during liver fibrosis development. PLoS One 7:1–14. doi:10.1371/journal.pone.0045285. One of the first papers that demonstrate the role of NOX4 during liver fibrosis and TGF-β mediated apoptosis
11. Jiang JX, Chen X, Serizawa N et al (2012) Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo. Free Radic Biol Med 53:289–296. doi:10.1016/j.freeradbiomed.2012.05.007
12. •• Ding N, Yu RT, Subramaniam N, et al. (2013) A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell 153:601–613. doi:10.1016/j.cell.2013.03.028. This study demonstrates the ability of VDR to inhibit TGF-β effects on HSC activation and liver fibrosis by interacting with Smad3
13. • Liu Y, Liu H, Meyer C, et al. (2013) Transforming growth factor-β-mediated connective tissue growth factor (CTGF) expression in hepatic stellate cells requires Stat3 signaling activation. J Biol Chem 288:30708–19. doi:10.1074/jbc.M113.478685. This work demonstrates Stat3 as important downstream signaling molecule to TGF-β/ALK5 in mediating CTGF expression
14. • Ding Z, Jin G, Liang H, et al. (2013) Transforming growth factor-β induces expression of connective tissue growth factor in hepatic progenitor cells through Smad independent signaling. Cell Signal 25:1981–92. doi:10.1016/j.cellsig.2013.05.027. This Study provides an evidence for the role of HPCs in liver fibrosis and suggests that the production of CTGF by TGF-β in HPCs is mediated by activated MAPK
15. •• Tomita K, Teratani T, Suzuki T, et al. (2013) Free cholesterol accumulation in hepatic stellate cells: Mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology 59:154-69. doi:10.1002/hep.26604. An elegant study demonstrating that free cholesterol in HSCs increases the availability of TLR4 and senstizes HSCs to TGF β action, thereby aggravating liver fibrosis in NASH
16. •• Tomita K, Teratani T, Suzuki T, et al. (2014) Acyl-CoA:cholesterol acyltransferase 1 mediates liver fibrosis by regulating free cholesterol accumulation in hepatic stellate cells. J Hepatol 61:98–106. doi:10.1016/j.jhep.2014.03.018. An interesting study illustrating Acyl-coA regulation as new therapeutic target to treat liver fibrosis
17. Liu C, Chen X, Yang L et al (2014) Transcriptional repression of the transforming growth factor-β (TGF-β) pseudoreceptor BMP and activin membrane-bound inhibitor (BAMBI) by nuclear factor κB (NF-κB) p50 enhances TGF-β signaling in hepatic stellate cells. J Biol Chem 289:7082–7091. doi:10.1074/jbc.M113.543769
18. Jia D, Duan F, Peng P et al (2013) Up-regulation of RACK1 by TGF-β1 promotes hepatic fibrosis in mice. PLoS ONE 8:e60115. doi:10.1371/journal.pone.0060115
19. Liu M, Peng P, Wang J et al (2015) RACK1-mediated translation control promotes liver fibrogenesis. Biochem Biophys Res Commun 463:255–261. doi:10.1016/j.bbrc.2015.05.040
20. Li L, Wang J-Y, Yang C-Q, Jiang W (2012) Effect of RhoA on transforming growth factor β1-induced rat hepatic stellate cell migration. Liver Int 32:1093–1102. doi:10.1111/j.1478-3231.2012.02809.x
21. •• Cao S, Yaqoob U, Das A, et al. (2010) Neuropilin-1 promotes cirrhosis of the rodent and human liver by enhancing PDGF/TGF-β signaling in hepatic stellate cells. J Clin Invest 120:2379–2394. doi:10.1172/JCI41203. This study reports participation of Neuropilin-1, the axonal guidance molecule, in liver cirrhosis via enhancing PDGF/TGF-β signaling in HSCs
22. Shah R, Reyes-Gordillo K, Arellanes-Robledo J et al (2013) TGF-β1 up-regulates the expression of PDGF-β receptor mRNA and induces a delayed PI3K-, AKT-, and p70(S6 K) -dependent proliferative response in activated hepatic stellate cells. Alcohol Clin Exp Res 37:1838–1848. doi:10.1111/acer.12167
23. Song Y, Zhan L, Yu M et al (2014) TRPV4 channel inhibits TGF-β1-induced proliferation of hepatic stellate cells. PLoS One 9:e101179. doi:10.1371/journal.pone.0101179
24. Fang L, Huang C, Meng X et al (2014) TGF-β1-elevated TRPM7 channel regulates collagen expression in hepatic stellate cells via TGF-β1/Smad pathway. Toxicol Appl Pharmacol 280:335–344. doi:10.1016/j.taap.2014.08.006
25. •• Mair M, Zollner G, Schneller D, et al. (2010) Signal transducer and activator of transcription 3 protects from liver injury and fibrosis in a mouse model of sclerosing cholangitis. Gastroenterology 138:2499–2508. doi:10.1053/j.gastro.2010.02.049. An important work showing that inactivation of Stat3 in hepatocytes and cholangiocytes of Mdr2ko mice aggravated bile acid-induced liver injury and fibrosis
26. Ogata H, Chinen T, Yoshida T et al (2006) Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-β1 production. Oncogene 25:2520–2530. doi:10.1038/sj.onc.1209281
27. Xu M-Y, Hu J-J, Shen J et al (2014) Stat3 signaling activation crosslinking of TGF-β1 in hepatic stellate cell exacerbates liver injury and fibrosis. Biochim Biophys Acta 1842:1–9. doi:10.1016/j.bbadis.2014.07.025
28. • Narmada BC, Chia SM, Tucker-Kellogg L, Yu H (2013) HGF regulates the activation of TGF-β1 in rat hepatocytes and hepatic stellate cells. J Cell Physiol 228:393–401. doi:10.1002/jcp.24143. This study examines crosstalk between HGF and TGF-β suggesting that HGF decreases TGF-β levels through induction of plasmin
29. • Woodhoo A, Iruarrizaga-Lejarreta M, Beraza N, et al. (2012) Human antigen R contributes to hepatic stellate cell activation and liver fibrosis. Hepatology 56:1870–1882. doi:10.1002/hep.25828 This study documents that RBP human antigen R (HuR) is fibrogenic by sensitizing activated HSC to PDGF and TGF-β
30. Yang JW, Hien TT, Lim SC et al (2014) Pin1 induction in the fibrotic liver and its roles in TGF-β1 expression and Smad2/3 phosphorylation. J Hepatol 60:1235–1241. doi:10.1016/j.jhep.2014.02.004
31. Bowen T, Jenkins RH, Fraser DJ (2013) MicroRNAs, transforming growth factor β-1, and tissue fibrosis. J Pathol 229:274–285. doi:10.1002/path.4119
32. Li ZJ, Ou-Yang PH, Han XP (2014) Profibrotic effect of miR-33a with Akt activation in hepatic stellate cells. Cell Signal 26:141–148. doi:10.1016/j.cellsig.2013.09.018
33. Hu J, Chen C, Liu Q et al (2015) The role of the miR-31/FIH1 pathway in TGF-β-induced liver fibrosis. Clin Sci 129:305–317. doi:10.1042/CS20140012
34. • Mungunsukh O, Day RM (2013) Transforming growth factor-β1 selectively inhibits hepatocyte growth factor expression via a micro-RNA-199-dependent posttranscriptional mechanism. Mol Biol Cell 24:2088–97. doi:10.1091/mbc.E13-01-0017. Another interesting study that shows the crosstalk between TGF-β and HGF and the capability of TGF-β to inhibit HGF by microRNA-199
35. Zheng J, Lin Z, Dong P et al (2013) Activation of hepatic stellate cells is suppressed by microRNA-150. Int J Mol Med 32:17–24. doi:10.3892/ijmm.2013.1356
36. • Roderburg C, Luedde M, Vargas Cardenas D, et al. (2013) MiR-133a mediates TGF-β-dependent derepression of collagen synthesis in hepatic stellate cells during liver fibrosis. J Hepatol 58:736–742. doi: 10.1016/j.jhep.2012.11.022. The study shows the antifibrotic role of MiR-133a in liver and illustrates its potential as target for diagnostics and therapy
37. Xiao X, Huang C, Zhao C et al (2015) Regulation of myofibroblast differentiation by miR-424 during epithelial-to-mesenchymal transition. Arch Biochem Biophys 566:49–57. doi:10.1016/j.abb.2014.12.007
38. Zhu D, He X, Duan Y et al (2014) Expression of microRNA-454 in TGF-β1-stimulated hepatic stellate cells and in mouse livers infected with Schistosoma japonicum. Parasit Vectors 7:148. doi:10.1186/1756-3305-7-148
39. • He Y, Huang C, Sun X, et al. (2012) MicroRNA-146a modulates TGF-β1-induced hepatic stellate cell proliferation by targeting SMAD4. Cell Signal 24:1923–1930. doi:10.1016/j.cellsig.2012.06.003. The study shows the ability of MiR-146a to inhibit TGF-β activity through decreasing Smad4
40. Tu X, Zheng X, Li H et al (2015) MicroRNA-30 protects against carbon tetrachloride-induced liver fibrosis by attenuating transforming growth factor-β signaling in hepatic stellate cells. Toxicol Sci 146:157–169. doi:10.1093/toxsci/kfv081
41. Ellenrieder V, Buck A, Harth ANA et al (2004) KLF11 mediates a critical mechanism in TGF beta signaling that is inactivated by ERK-MAPK in pancreatic cancer cells. Gastroenterology 5085:607–620. doi:10.1053/S0016-5085(04)00864-9
42. • Yu F, Guo Y, Chen B, et al. (2015) MicroRNA-17-5p activates hepatic stellate cells through targeting of Smad7. Lab Investig 95:781–789. doi:10.1038/labinvest.2015.58. The authors show that MiR-175-5p is targeting Smad7 during HSC activation, therewith enhancing TGF-β action and fibrogenesis
43. Sun X, He Y, Ma T-T et al (2014) Participation of miR-200a in TGF-β1-mediated hepatic stellate cell activation. Mol Cell Biochem 388:11–23. doi:10.1007/s11010-013-1895-0
44. Zhang Z, Zha Y, Hu W et al (2013) The autoregulatory feedback loop of MicroRNA-21/programmed cell death protein 4/Activation protein-1 (MiR-21/PDCD4/AP-1) as a driving force for hepatic fibrosis development. J Biol Chem 288:37082–37093. doi:10.1074/jbc.M113.517953
45. Zhang Z, Gao Z, Hu W et al (2013) 3,3′-Diindolylmethane ameliorates experimental hepatic fibrosis via inhibiting miR-21 expression. Br J Pharmacol 170:649–660. doi:10.1111/bph.12323
46. Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425:577–584. doi:10.1038/nature02006
47. • Zhang L, Liu C, Meng X, et al. (2014) Smad2 protects against TGF-β1/Smad3-mediated collagen synthesis in human hepatic stellate cells during hepatic fibrosis. Mol Cell Biochem 400:17–28. doi:10.1007/s11010-014-2258-1. This study provides evidence for opposite roles of Smad2 and Smad3 in liver fibrosis
48. Yoshida K, Matsuzaki K (2012) Differential regulation of TGF-β/Smad signaling in hepatic stellate cells between acute and chronic liver injuries. Front Physiol 3:1–7. doi:10.3389/fphys.2012.00053
49. Matsuzaki K (2012) Smad phosphoisoform signals in acute and chronic liver injury: similarities and differences between epithelial and mesenchymal cells. Cell Tissue Res 347:225–243. doi:10.1007/s00441-011-1178-6
50. • Yamaguchi T, Matsuzaki K, Inokuchi R, et al. (2013) Phosphorylated Smad2 and Smad3 signaling: Shifting between tumor suppression and fibro-carcinogenesis in chronic hepatitis C. Hepatol Res 43:1327–1342. doi:10.1111/hepr.12082. An interesting study that describes variant biological effects of differently phosphorylated forms of Smad2 and Smad3 at linker and/or C-terminal regions
51. Feng T, Dzieran J, Gu X et al (2015) Smad7 regulates compensatory hepatocyte proliferation in damaged mouse liver and positively relates to better clinical outcome in human hepatocellular carcinoma. Clin Sci 128:761–774. doi:10.1042/CS20140606
52. Wang J, Zhao J, Chu ESH et al (2013) Inhibitory role of Smad7 in hepatocarcinogenesis in mice and in vitro. J Pathol 230:441–452. doi:10.1002/path.4206
53. Xia H, Ooi LLPJ, Hui KM (2013) MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology 58:629–641. doi:10.1002/hep.26369
54. Muñoz-Félix JM, González-Núñez M, López-Novoa JM (2013) ALK1-Smad1/5 signaling pathway in fibrosis development: friend or foe? Cytokine Growth Factor Rev 24:523–537. doi:10.1016/j.cytogfr.2013.08.002
55. • Wiercinska E, Wickert L, Denecke B, et al. (2006) Id1 is a critical mediator in TGF-β-induced transdifferentiation of rat hepatic stellate cells. Hepatology 43:1032–1041. doi:10.1002/hep.21135. The study was the first to identify ALK1/Smad1 as downstream mediators of TGF-β signaling in HSCs and a critical role in fibrogenesis for its target gene Id1
56. Muñoz-Félix JM, Perretta-Tejedor N, Eleno N et al (2014) ALK1 heterozygosity increases extracellular matrix protein expression, proliferation and migration in fibroblasts. Biochim Biophys Acta 1843:1111–1122. doi:10.1016/j.bbamcr.2014.02.017
57. An P, Tian Y, Chen M, Luo H (2012) Ca(2 +)/calmodulin- dependent protein kinase II mediates transforming growth factor-β-induced hepatic stellate cells proliferation but not in collagen α1(I) production. Hepatol Res 42:806–818. doi:10.1111/j.1872-034X.2012.00983.x
58. De Minicis S, Rychlicki C, Agostinelli L et al (2013) Semaphorin 7A contributes to TGF-β-mediated liver fibrogenesis. Am J Pathol 183:820–830. doi:10.1016/j.ajpath.2013.05.030
59. • Tu K, Li J, Verma VK, et al. (2014) VASP promotes TGF-β activation of hepatic stellate cells by regulating Rab11 dependent plasma membrane targeting of TGF-β receptors. Hepatology 1–54. doi:10.1002/hep.27251. The study shows that VASP binds to TβRII in HSCs, thus increasing sensitivity to TGF-β
60. Liu C, Li J, Xiang X et al (2014) PDGF receptor-α promotes TGF-β signaling in hepatic stellate cells via transcriptional and posttranscriptional regulation of TGF-β receptors. AJP Gastrointest Liver Physiol 307:G749–G759. doi:10.1152/ajpgi.00138.2014
61. Nyati S, Schinske-sebolt K, Pitchiaya S et al (2015) The kinase activity of the Ser/Thr kinase BUB1 promotes TGF-b signaling. Sci Signal 8:1–12. doi:10.1126/scisignal.2005379
62. Shukla A, Edwards R, Yang Y et al (2014) CLIC4 regulates TGF-β-dependent myofibroblast differentiation to produce a cancer stroma. Oncogene 33:842–850. doi:10.1038/onc.2013.18
63. • Shukla A, Malik M, Cataisson C, et al. (2009) TGF-β signalling is regulated by Schnurri-2-dependent nuclear translocation of CLIC4 and consequent stabilization of phospho-Smad2 and 3. Nat Cell Biol 11:777–784. doi: 10.1038/ncb1885. The study reports that CLIC4 stabilizes pSmad2/3 in the nucleus thereby enhancing TGF-β signaling
64. Miyazono K (2000) TGF-β signaling by Smad proteins. Cytokine Growth Factor Rev 11:15–22. doi:10.1016/S1359-6101(99)00025-8
65. Bian E-B, Huang C, Wang H et al (2014) Repression of Smad7 mediated by DNMT1 determines hepatic stellate cell activation and liver fibrosis in rats. Toxicol Lett 224:175–185. doi:10.1016/j.toxlet.2013.10.038
66. •• Seki E, De Minicis S, Osterreicher CH, et al. (2007) TLR4 enhances TGF-β signaling and hepatic fibrosis. Nat Med 13:1324–1332. doi:10.1038/nm1663. This elegant study identifies HSC as primary target cell type of LPS in liver fibrosis, signaling via TLR4 and downregulating TGF-β decoy receptor BAMBI to enhance TGF-β activity and HSC activation
67. Friedman SL (2007) A deer in the headlights: BAMBI meets liver fibrosis. Nat Med 13:1281–1282. doi:10.1038/nm1107-1281
68. Maxwell MA, Cleasby ME, Harding A et al (2005) Nur77 regulates lipolysis in skeletal muscle cells: evidence for cross-talk between the β-adrenergic and an orphan nuclear hormone receptor pathway. J Biol Chem 280:12573–12584. doi:10.1074/jbc.M409580200
69. Pei L, Waki H, Vaitheesvaran B et al (2006) NR4A orphan nuclear receptors are transcriptional regulators of hepatic glucose metabolism. Nat Med 12:1048–1055. doi:10.1038/nm1471
70. Hanna RN, Carlin LM, Hubbeling HG et al (2011) The transcription factor NR4A1 (Nur77) controls bone marrow differentiation and the survival of Ly6C- monocytes. Nat Immunol 12:778–785. doi:10.1038/ni.2063
71. • Zhou F, Drabsch Y, Dekker TJ a, et al. (2014) Nuclear receptor NR4A1 promotes breast cancer invasion and metastasis by activating TGF-β signalling. Nat Commun 5:3388. doi:10.1038/ncomms4388. The study describes NR4A1 as a strong activator of TGF-β signaling in breast cancer through its ability to induce Smad7 degradation
72. •• Palumbo-Zerr K, Zerr P, Distler A, et al. (2015) Orphan nuclear receptor NR4A1 regulates transforming growth factor-β signaling and fibrosis. Nat Med 21:150–158. doi:10.1038/nm.3777. In contrary to Zhou et al (2014), this study introduces NR4A1 as a TGF-β inhibitor describing a disturbed feedback loop between TGF-β and NR4A1 in different fibrotic diseases and illustrates usage of a NR4A1 agonist as treatment approach to rebalance this disturbed loop
73. • Lim JY, Oh M a., Kim WH, et al. (2012) AMP-activated protein kinase inhibits TGF-β-induced fibrogenic responses of hepatic stellate cells by targeting transcriptional coactivator p300. J Cell Physiol 227:1081–1089. doi:10.1002/jcp.22824. The study provides evidence for an interaction between AMPK and TGF-β in HSCs. AMPK inhibits TGF-β signaling through targeting p300
74. Sun H, Ghaffari S, Taneja R (2007) bHLH-orange transcription factors in development and cancer. Transl Oncogenomics 2:107–120
75. Acharjee S, Chung T-K, Gopinadhan S et al (2014) Sharp-1 regulates TGF-β signaling and skeletal muscle regeneration. J Cell Sci 127:599–608. doi:10.1242/jcs.136648
76. Hong IH, Park SJ, Goo MJ et al (2013) JNK1 and JNK2 regulate alpha-SMA in hepatic stellate cells during CCl4-induced fibrosis in the rat liver. Pathol Int 63:483–491. doi:10.1111/pin.12094
77. • Jiang Y, Wu C, Boye A, et al. (2015) MAPK inhibitors modulate Smad2/3/4 complex cyto-nuclear translocation in myofibroblasts via Imp7/8 mediation. Mol Cell Biochem. doi:10.1007/s11010-015-2443-x. The study shows crosstalk between MAPK and TGF-β signaling. Specific MAPK inhibitors blocked nuclear translocation of Smad2/3/4 complexes through inhibition of Imp7/8
78. Sullivan B, Kassel K, Manley S et al (2011) Regulation of transforming growth factor-1-dependent integrin 6 expression by p38 mitogen-activated protein kinase in bile duct epithelial cells. J Pharmacol Exp Ther 337:471–478. doi:10.1124/jpet.110.177337.Sullivan
79. Huang G, Besner GE, Brigstock DR (2012) Heparin-binding epidermal growth factor-like growth factor suppresses experimental liver fibrosis in mice. Lab Investig 92:703–712. doi:10.1038/labinvest.2012.3
80. Takemura T, Yoshida Y, Kiso S et al (2013) Conditional loss of heparin-binding EGF-like growth factor results in enhanced liver fibrosis after bile duct ligation in mice. Biochem Biophys Res Commun 437:185–191. doi:10.1016/j.bbrc.2013.05.097
81. • Fabre T, Kared H, Friedman SL, Shoukry NH (2014) IL-17A enhances the expression of profibrotic genes through upregulation of the TGF-β receptor on hepatic stellate cells in a JNK-dependent manner. J Immunol 193:3925–3933. doi:10.4049/jimmunol.1400861. The study identifies cooperative signaling between IL17A and TβRII in HSCs, thereby enhancing TGF-β signaling at suboptimal TGF-β doses
82. • Liu Y, Meyer C, Müller A, et al. (2011) IL-13 induces connective tissue growth factor in rat hepatic stellate cells via TGF-β-independent Smad signaling. J Immunol 187:2814–2823. doi:10.4049/jimmunol.1003260. The studies describes how IL-13 and TGF-β signaling pathways communicate to integrate induction of CTGF expression in HSCs
83. • Weng HL, Liu Y, Chen JL, et al. (2009) The etiology of liver damage imparts cytokines transforming growth factor-β 1 or interleukin-13 as driving forces in fibrogenesis. Hepatology 50:230–243. doi:10.1002/hep.22934. Here, the authors show in human patients with CLD that depending on the etiology, either TGF-β or IL-13 can be the driver of liver fibrosis
84. • Carmona-Cuenca I, Roncero C, Sancho P, et al. (2008) Upregulation of the NADPH oxidase NOX4 by TGF-β in hepatocytes is required for its pro-apoptotic activity. J Hepatol 49:965–976. doi:10.1016/j.jhep.2008.07.021. The study shows requirement of upregulated NOX4 in TGF-β-induced hepatocyte apoptosis
85. Murillo MM, del Castillo G, Sánchez A et al (2005) Involvement of EGF receptor and c-Src in the survival signals induced by TGF-β1 in hepatocytes. Oncogene 24:4580–4587. doi:10.1038/sj.onc.1208664
86. • Meyer C, Godoy P, Bachmann A, et al. (2011) Distinct role of endocytosis for Smad and non-Smad TGF-β signaling regulation in hepatocytes. J Hepatol 55:369–378. doi:10.1016/j.jhep.2010.11.027. This work highlights the importance of endocytosis in regulating TGF-β signaling in hepatocytes
87. • Meyer C, Liu Y, Kaul a, et al. (2013) Caveolin-1 abrogates TGF-β mediated hepatocyte apoptosis. Cell Death Dis 4:e466. doi:10.1038/cddis.2012.204. This work shows Caveolin-1 as important hepatocyte fate determinant for TGF-β effects. Knockdown of Caveolin-1 sensitized hepatocytes for TGF-β mediated apoptosis through downregulating AKT phosphorylation
88. • Moreno-Càceres J, Caja L, Mainez J, et al. (2014) Caveolin-1 is required for TGF-β-induced transactivation of the EGF receptor pathway in hepatocytes through the activation of the metalloprotease TACE/ADAM17. Cell Death Dis 5:e1326. doi:10.1038/cddis.2014.294. This study shows a link between TGF-β and the EGF receptor via Caveolin
89. •• Godoy P, Hengstler JG, Ilkavets I, et al. (2009) Extracellular matrix modulates sensitivity of hepatocytes to fibroblastoid dedifferentiation and transforming growth factor-β-induced apoptosis. Hepatology 49:2031–2043. doi:10.1002/hep.22880. This study demonstrates that cultured hepatocytes undergo cellular stress with activation of survival pathways, which protect against TGF-β dependent apoptosis
90. •• Dooley S, Hamzavi J, Ciuclan L, et al. (2008) Hepatocyte-specific Smad7 expression attenuates TGF-β-mediated fibrogenesis and protects against liver damage. Gastroenterology 135:642–659. doi:10.1053/j.gastro.2008.04.038. This investigation shows that overexpression of TGF-β antagonist Smad7 in hepatocytes interferes with liver fibrogenesis in CCl4 treated mice
91. •• Yang L, Roh YS, Song J, et al. (2014) Transforming growth factor β signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice. Hepatology 59:483–495. doi:10.1002/hep.26698. This paper convincingly shows participation of hepatocyte TGF-β signaling in the generation of a NASH phenotype in mice fed a high fat diet
92. •• Yang L, Inokuchi S, Roh YS, et al. (2013) Transforming growth factor-β signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1. Gastroenterology 144:1042–1054.e4. doi:10.1053/j.gastro.2013.01.056. This paper shows that TAK1 is a critical TGF-β signaling regulator in hepatocytes that reduces pro-apoptotic activity by activating cell survival pathways. Its abrogation leads to massive TGF-β mediated hepatocyte death, proliferative activity and inflammation mediated HCC development
93. Luedde T, Kaplowitz N, Schwabe RF (2014) Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology 147(765–783):e4. doi:10.1053/j.gastro.2014.07.018
94. −/− mice with lentiviral-GFP under the control of a hepatocyte-specific promoter. With that approach, the authors show that apoptosis and phagocytosis of hepatocytes directly induce HSC activation and initiation of fibrosis, and that NOX2, the phagocytic NADPH oxidase, plays a key role in this process
95. • Huebener P, Pradere J, Hernandez C, et al. (2015) The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis. 125:539–550. doi:10.1172/JCI76887.DAMP. The study shows that hepatocytes under stress send out signals termed Damage-associated molecular patterns to initiate cellular reactions in injured liver tissue; in this case HMGB1, which amplifies neutrophil-mediated injury via its receptor RAGE
96. • Jung Y, Witek RP, Syn W-K, et al. (2010) Signals from dying hepatocytes trigger growth of liver progenitors. Gut 59:655–665. doi:10.1136/gut.2009.204354. The study similarly shows that dying hepatocytes overexpress Hh ligands, which provide a survival signal for progenitor cells and myofibroblasts thus triggering wound healing/fibrogenesis
97. Sakata K, Eda S, Lee ES et al (2014) Neovessel formation promotes liver fibrosis via providing latent transforming growth factor-β. Biochem Biophys Res Commun 443:950–956. doi:10.1016/j.bbrc.2013.12.074
98. Xie G, Diehl AM (2013) Evidence for and against epithelial-to-mesenchymal transition in the liver. Am J Physiol Gastrointest Liver Physiol 305:G881–G890. doi:10.1152/ajpgi.00289.2013
99. Lee SJ, Kim KH, Park KK (2014) Mechanisms of fibrogenesis in liver cirrhosis: the molecular aspects of epithelial-mesenchymal transition. World J Hepatol 6:207–216. doi:10.4254/wjh.v6.i4.207
100. Zeisberg M, Yang C, Martino M et al (2007) Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 282:23337–23347. doi:10.1074/jbc.M700194200
101. •• Österreicher CH, Penz-österreicher M, Grivennikov SI, Guma M (2010) Fibroblast-specific protein 1 identifies an inflammatory subpopulation of macrophages in the liver. doi:10.1073/pnas.1017547108. The study identifies FSP1, previously described as a marker to identify hepatocytes undergoing EMT during fibrogenesis, as a specific marker for a subpoulation of macrophages
102. •• Taura K, Miura K, Iwaisako K, et al. (2010) Hepatocytes do not undergo epithelial-mesenchymal transition in liver fibrosis in mice. Hepatology 51:1027–1036. doi:10.1002/hep.23368. An interesting study using lineage tracing to confirm that there is no change of the morphology and no expression of EMT markers in hepatocytes of CCl4-treated mice challenging the concept that hepatocytes can undergo EMT
103. Bi WR, Xu GT, Lv LX, Yang CQ (2014) The ratio of transforming growth factor-β1/bone morphogenetic protein-7 in the progression of the epithelial-mesenchymal transition contributes to rat liver fibrosis. Genet Mol Res 13:1005–1014. doi:10.4238/2014.February.20.2
104. Bi WR, Jin CX, Xu GT, Yang CQ (2012) Bone morphogenetic protein-7 regulates Snail signaling in carbon tetrachloride-induced fibrosis in the rat liver. Exp Ther Med 4:1022–1026. doi:10.3892/etm.2012.720
105. • Wang S-L, Yang C, Qi X-L, et al. (2013) Inhibitory effect of bone morphogenetic protein-7 on hepatic fibrosis in rats. Int J Clin Exp Pathol 6:897–903. The study shows the ability of BMP-7 to attenuate liver fibrosis via inhibition of TGF-β1 signaling
106. Wang L, Dong J, Xiong L et al (2014) BMP-7 attenuates liver fibrosis via regulation of epidermal growth factor receptor. Int J Clin Exp Pathol 7:3537–3547
107. Chen J, Xia Y, Lin X et al (2014) Smad3 signaling activates bone marrow-derived fibroblasts in renal fibrosis. Lab Investig 94:545–556. doi:10.1038/labinvest.2014.43
108. Singh V, Barbosa FL, Torricelli A a M, et al. (2014) Transforming growth factor-β and platelet-derived growth factor modulation of myofibroblast development from corneal fibroblasts invitro. Exp Eye Res 120:152–160. doi: 10.1016/j.exer.2014.01.003
109. • Kim S, Lim JH, Woo CH (2013) ERK5 inhibition ameliorates pulmonary fibrosis via regulating Smad3 acetylation. Am J Pathol 183:1758–1768. doi:10.1016/j.ajpath.2013.08.014. Interestingly, this study shows that ERK5 inhibition can antagonize TGF-β-mediated fibrogenic signaling through Smad3 acetylation instead through Smad3 phosphorylation
110. Liu N, He S, Ma L et al (2013) Blocking the Class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-β and EGFR signaling. PLoS One 8:1–12. doi:10.1371/journal.pone.0054001
111. Chen K-H, Hsu H-H, Lee C-C et al (2014) The AMPK agonist AICAR inhibits TGF-β1 induced activation of kidney myofibroblasts. PLoS One 9:e106554. doi:10.1371/journal.pone.0106554
112. • Duan W-J, Yu X, Huang X-R, et al. (2014) Opposing roles for Smad2 and Smad3 in peritoneal fibrosis in vivo and in vitro. Am J Pathol 184:2275–2284. doi:10.1016/j.ajpath.2014.04.014 A good study that expand our information about the specific roles that Smad2 and Smad3 play in organ fibrosis and confirm the results of Zhang et al (2014) in the liver
113. Stifano G, Affandi AJ, Mathes AL et al (2014) Chronic Toll-like receptor 4 stimulation in skin induces inflammation, macrophage activation, transforming growth factor-β signature gene expression, and fibrosis. Arthritis Res Ther 16:R136. doi:10.1186/ar4598
114. Sassoli C, Chellini F, Pini A et al (2013) Relaxin prevents cardiac fibroblast-myofibroblast transition via Notch-1-mediated inhibition of TGF-β/Smad3 signaling. PLoS One 8:1–12. doi:10.1371/journal.pone.0063896
115. Chen Y, Zheng S, Qi D et al (2012) Inhibition of notch signaling by a γ-secretase inhibitor attenuates hepatic fibrosis in rats. PLoS One 7:1–11. doi:10.1371/journal.pone.0046512
116. Calone I, Souchelnytskyi S (2012) Inhibition of TGF-β signaling and its implications in anticancer treatments. Exp Oncol 34:9–16
117. Karkampouna S, Goumans M-J, ten Dijke P et al (2015) Inhibition of TGF-β type I receptor activity facilitates liver regeneration upon acute CCl4 intoxication in mice. Arch Toxicol. doi:10.1007/s00204-014-1436-y
118. Dooley S, Ten Dijke P (2012) TGF-β in progression of liver disease. Cell Tissue Res 347:245–256. doi:10.1007/s00441-011-1246-y
119. •• Henderson NC, Arnold TD, Katamura Y, et al. (2013) Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med 19:1617–24. doi:10.1038/nm.3282. An elegant study that used Cre/Loxp technique to specifically target αv integrin in different organs. The results show that αv integrin depletion is effective in protecting the mice against CCl4-induced liver fibrosis and attentuated also renal and pulmonary fibrosis, highlighting αv integrin as general therapeutic target in variant fibrotic diseases
120. Jiang Y, Wang C, Li Y-Y et al (2014) Mistletoe alkaloid fractions alleviates carbon tetrachloride-induced liver fibrosis through inhibition of hepatic stellate cell activation via TGF-β/Smad interference. J Ethnopharmacol 158:230–238. doi:10.1016/j.jep.2014.10.028
121. Huang W, Li L, Tian X et al (2014) Astragalus and Paeoniae Radix Rubra extract (APE) inhibits hepatic stellate cell activation by modulating transforming growth factor-β/smad pathway. Mol Med Rep. doi:10.3892/mmr.2014.3026
122. Tang LX, He RH, Yang G et al (2012) Asiatic acid inhibits liver fibrosis by blocking TGF-β/smad signaling in vivo and in vitro. PLoS One. doi:10.1371/journal.pone.0031350
123. 4 -treated rats. J Med Food 18:290–298. doi:10.1089/jmf.2013.0179
124. • Chiu YS, Wei CC, Lin YJ, et al. (2014) Il-20 and IL-20R1 antibodies protect against liver fibrosis. Hepatology 1003–1014. doi:10.1002/hep.27189. The study shows the detrimental effects of IL-20 during liver fibrosis in human and animals illustrating that blocking antibodies for IL-20 and IL-20R1 are potential therapeutic agents
125. Fan X, Zhang Q, Li S et al (2013) Attenuation of CCl4-induced hepatic fibrosis in mice by vaccinating against TGF-β1. PLoS One 8:1–13. doi:10.1371/journal.pone.0082190
126. Van Beuge MM, Prakash J, Lacombe M et al (2013) Enhanced effectivity of an ALK5-inhibitor after cell-specific delivery to hepatic stellate cells in mice with liver injury. PLoS One 8:1–9. doi:10.1371/journal.pone.0056442
127. Aoyama T, Paik Y-H, Watanabe S et al (2012) Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatology 56:2316–2327. doi:10.1002/hep.25938
128. Pardali E, Dijke P (2009) Transforming growth factor-β signaling and tumor angiogenesis. Mol Cell 14:4848–4861